Why Pfizer Likely Isn't Done With M&A After the Seagen Deal

David Jagielski, The Motley Fool

March 22, 2023 at 10:45 a.m.·3 min read

Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally.